相关实验视频
Updated: Jan 28, 2026
06:19
Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
Published on: May 16, 2025
1.4K
工程化益生菌微囊 联合封装柏柏林和黄素 诱导性结肠炎多协同疗法
Huanyu Li1,2, Chuanyu Zhang3,4, Ziwei Yang3,4
1Institute of Translational Medicine, School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, China.
Materials today. Bio
|January 26, 2026
概括
益生菌微囊同时提供柏柏林 (BBR) 和黄素 (CUR),在性结肠炎 (UC) 治疗中显示出协同作用的抗炎和抗氧化作用. 这种新的方法有效地针对关键信号通路,为UC提供了一个有前途的治疗策略.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 材料科学 材料科学 材料科学
背景情况:
- 性结肠炎 (UC) 由于炎症和氧化应激而带来治疗挑战.
- 现有的UC疗法存在局限性,需要新的方法.
- 柏柏林 (BBR) 和黄素 (CUR) 显示出协同UC治疗的潜力,但由于溶解性和生物可用性差,需要改进的输送系统.
研究的目的:
- 构建益生菌微囊 (BBR/CUR@MC) 以同时提供BBR和CUR.
- 在UC模型中研究BBR/CUR@MC的治疗机制.
- 与现有治疗方法相比,评估BBR/CUR@MC的疗效.
主要方法:
- 网络药理学预测了UC中BBR和CUR的治疗目标和途径.
- BBR/CUR@MC是使用微流体电喷技术制备的.
- 在DSS诱导的UC小鼠模型中的体内研究通过转录组分析评估了结肠向,生物相容性,治疗效果和机制.
主要成果:
- 网络药理学确定了TNF和AGE-RAGE信号通路作为UC中BBR和CUR的关键目标.
- BBR/CUR@MC表现出良好的结肠向性和生物相容性.
- 口服BBR/CUR@MC显著缓解了结肠炎症,修复了肠道屏障,与单药微囊和5-ASA相比,显示出更好的治疗效果.
结论:
- 在UC治疗中,BBR/CUR@MC具有协同的抗炎和抗氧化作用.
- 治疗机制涉及调节TNF和AGE-RAGE信号通路.
- 这种配方为性结肠炎提供了一种新的多机制治疗策略.
相关概念视频
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
957
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
957
01:29Drugs for Treatment of Ulcerative Colitis in IBD
497
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
497
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
1.2K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
1.2K
00:49What is Genetic Engineering?
80.0K
Overview
80.0K
01:28Peptic Ulcer Disease II: Pathophysiology
2.0K
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
2.0K
01:30Peptic Ulcer Disease I: Introduction
785
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
785